• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Siderosis

Siderosis - 26 Studies Found

Completed : Efficacy Study in Removing Excess Iron From the Heart
:
  • Thalassemia Major
  • Hemosiderosis

: 2005-03-15
:
  • Drug: Ferriprox (deferiprone)
  • Drug: Desfer

Not yet recruiting : Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis
:
  • Amyloid Cerebral Angiopathy
  • Alzheimer Disease

: 2016-01-19
:
  • Device: Pet scan with FBB

Terminated : Clinical Importance of Treating Iron Overload in Sickle Cell Disease
:
  • Anemia, Sickle Cell
  • Transfusion Hemosiderosis

: 2009-09-21
: Drug: deferasirox Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron conc
Completed : Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
:
  • Anemia
  • Hemosiderosis

: 2005-10-14
: Drug: Deferasirox Deferasirox available as 125 mg, 250 mg or 500 mg tablets
Completed : Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
:
  • Iron Overload
  • Hemochromatosis
  • Hemosi
    : 2013-12-12
    : Other: MRI R2 MRI scan Other Name: Magnetic Resonanc
Completed : Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
: Beta-Thalassemia
: 2003-06-03
:
  • Drug: ICL670 Other Name: Defer

Completed : Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
:
  • Beta-thalassemia Major
  • Sickle Cell Disease
  • Iron : 2012-01-06
    :
    • Drug: DFP (ferriprox) and deferasirox (ICL 670)

Completed : ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
: Anemia
: 2007-04-25
: Drug: Deferasirox
Withdrawn : Treatment of Iron Overload Requiring Chelation Therapy
:
  • Transfusional Iron Overload
  • Iron Overload
  • Iron Chelation : 2013-08-20
    :
    • Drug: SPD602 32, 50 or 75 mg/k

Enrolling by invitation : A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
:
  • Thalassemia
  • Brain Function (Measured by ERP Level)

: 2013-08-07
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.